Monitoring glucose levels in women after gestational diabetes
Early Investigation of Glucose Monitoring After Gestational Diabetes (ENGAGED): Utility and Acceptability of Continuous Glucose Monitoring in the Early Postpartum Period After Gestational Diabetes Mellitus
This study is testing if wearing a continuous glucose monitor can help women who had gestational diabetes keep track of their blood sugar levels after giving birth.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Sponsor | Ohio State University Academic / other |
| Locations | 1 site (Columbus, Ohio) |
| Trial ID | NCT06184373 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the use of continuous glucose monitors (CGM) in postpartum women who have experienced gestational diabetes (GDM). Participants will wear a CGM device at 6-8 weeks postpartum to track their glucose levels and will complete surveys regarding their quality of life during this period. The goal is to assess the acceptability and feasibility of CGM as a screening tool for ongoing dysglycemia in women with a history of GDM, as traditional follow-up methods have low adherence rates. Data collected may inform future studies on the effectiveness of CGM in this population.
Who should consider this trial
Good fit: Ideal candidates are postpartum women who have had a recent pregnancy affected by gestational diabetes.
Not a fit: Patients with pregestational diabetes or those using diabetes medications immediately after delivery may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve postpartum glucose monitoring and follow-up care for women with a history of gestational diabetes.
How similar studies have performed: While the use of CGM in gestational diabetes is not extensively studied, similar approaches in diabetes management have shown promise, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women with a viable singleton intrauterine pregnancy * Able to understand the study, and having understood, provide written informed consent in English * Recent pregnancy affected by gestational diabetes Exclusion Criteria: * Pregestational Diabetes (Type I or Type II) * Continued use of diabetes medications (including metformin and insulin) immediately after delivery * Preterm delivery (\< 37 weeks gestation) * Twin or higher order gestation * No access to a smartphone * Unable or unwilling to wear CGM or return for follow up at postpartum mother-infant dyad clinic * Participation in this trial in a prior pregnancy * History of skin allergy to adhesive products or CGM
Where this trial is running
Columbus, Ohio
- Ohio State University Medical Center — Columbus, Ohio, United States (Recruiting)
Study contacts
- Study coordinator: Rachel Gordon, MD, MPH
- Email: rachel.gordon@osumc.edu
- Phone: 614-293-7980
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.